4-oxo-N-(4-hydroxyphenyl)retinamide: Two Independent Ways to Kill Cancer Cells by Tiberio, Paola et al.
4-oxo-N-(4-hydroxyphenyl)retinamide: Two Independent
Ways to Kill Cancer Cells
Paola Tiberio*, Elena Cavadini, Gabriella Abolafio, Franca Formelli, Valentina Appierto
Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS ‘‘Istituto Nazionale dei Tumori’’, Milan, Italy
Abstract
Background: The retinoid 4-oxo-N-(4-hydroxyphenyl)retinamide (4-oxo-4-HPR) is a polar metabolite of fenretinide (4-HPR)
very effective in killing cancer cells of different histotypes, able to inhibit 4-HPR-resistant cell growth and to act
synergistically in combination with the parent drug. Unlike 4-HPR and other retinoids, 4-oxo-4-HPR inhibits tubulin
polymerization, leading to multipolar spindle formation and mitotic arrest. Here we investigated whether 4-oxo-4-HPR, like
4-HPR, triggered cell death also via reactive oxygen species (ROS) generation and whether its antimicrotubule activity was
related to a ROS-dependent mechanism in ovarian (A2780), breast (T47D), cervical (HeLa) and neuroblastoma (SK-N-BE)
cancer cell lines.
Methodology/Principal Findings: We provided evidence that 4-oxo-4-HPR, besides acting as an antimicrotubule agent,
induced apoptosis through a signaling cascade starting from ROS generation and involving endoplasmic reticulum (ER)
stress response, Jun N-terminal Kinase (JNK) activation, and upregulation of the proapoptotic PLAcental Bone
morphogenetic protein (PLAB). Through time-course analysis and inhibition of the ROS-related signaling pathway
(upstream by vitamin C and downstream by PLAB silencing), we demonstrated that the antimitotic activity of 4-oxo-4-HPR
was independent from the oxidative stress induced by the retinoid. In fact, ROS generation occurred earlier than mitotic
arrest (within 30 minutes and 2 hours, respectively) and abrogation of the ROS-related signaling pathway did not prevent
the 4-oxo-4-HPR-induced mitotic arrest.
Conclusions/Significance: These data indicate that 4-oxo-4-HPR anticancer activity is due to at least two independent
mechanisms and provide an explanation of the ability of 4-oxo-4-HPR to be more potent than the parent drug and to be
effective also in 4-HPR-resistant cell lines. In addition, the double mechanism of action could allow 4-oxo-4-HPR to efficiently
target tumour and to eventually counteract the development of drug resistance.
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Introduction
Retinoids are a class of chemical compounds structurally related
to vitamin A that modulate fundamental cellular processes,
including cell proliferation, differentiation and apoptosis [1]. The
synthetic retinoid fenretinide or N-(4-hydroxyphenyl)retinamide
(4-HPR) is a non toxic analog of all-trans retinoic acid [2] that has
already shown promising results in preneoplastic [3–5] and
neoplastic conditions [6,7]. In cultured cells, 4-HPR has been
shown to induce growth inhibition and apoptosis in various cancer
cell lines and different mechanisms of action have been proposed,
including the generation of reactive oxygen species (ROS) and
consequent oxidative stress [8,9]. We have recently reported that
in ovarian cancer cells, 4-HPR-induced apoptosis is mediated by
the proapoptotic PLAcental Bone morphogenetic protein (PLAB)
and that its upregulation by 4-HPR occurs through the activation
of a signaling cascade starting from increase of ROS generation,
leading to induction of endoplasmic reticulum (ER) stress response
and Jun N-terminal Kinase (JNK) activation [9,10]. From the
analysis of plasma samples of 4-HPR-treated patients, we have
identified a new 4-HPR polar metabolite, 4-oxo-N-(4-hydroxy-
phenyl)retinamide (4-oxo-4-HPR) [11], which is endowed with
promising biological properties [12]. 4-oxo-4-HPR elicits antipro-
liferative and apoptotic effects in various cancer cell lines (i.e.
ovarian, breast, and neuroblastoma tumour cell lines) and is two to
four times more effective than 4-HPR in inhibiting cell growth
[12]. Interestingly, 4-oxo-4-HPR is also effective in 4-HPR-
resistant cells and, in combination with 4-HPR, has a synergistic
effect [12]. Similarly to 4-HPR, the tumour growth-inhibitory
effects of 4-oxo-4-HPR are independent of nuclear retinoid
receptors (RARs). In addition, 4-HPR and 4-oxo-4-HPR share
several signaling intermediates, such as ROS generation, increase
of intracellular ceramide levels, and activation of caspase-3 and
caspase-9 [12]. Despites these similarities, 4-oxo-4-HPR seems to
have additional mechanisms of action compared to the parent
drug, also suggested by its ability to be effective in 4-HPR resistant
cells [12]. In fact, unlike 4-HPR, 4-oxo-4-HPR causes a marked
accumulation of cells in mitotic phase, specifically in pre-anaphase,
coupled with activation of the spindle checkpoint [13]. The 4-oxo-
4-HPR-induced arrest in mitosis is associated with aberrant
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13362spindle formation (i.e. multipolar organization without loss of
centrosome integrity), due to the ability of 4-oxo-4-HPR to target
microtubules and to inhibit tubulin polymerization through a
direct molecular interaction with tubulin [13].The present study
was planned to further dissect 4-oxo-4-HPR mechanisms of action
underlying its antiproliferative effect, investigating whether the
anticancer activity of the retinoid may arise also from its ability to
increase ROS generation and whether the antimitotic activity of
the retinoid is related to the oxidative stress. We have herein
demonstrated that, like 4-HPR, 4-oxo-4-HPR causes increase of
ROS generation, followed by induction of ER stress response,
activation of JNK and PLAB upregulation and that this signaling
cascade is partially involved in the antiproliferative effect of the
retinoid. Moreover, the 4-oxo-4-HPR antimitotic effect is
functionally independent from the abovementioned apoptotic
cascade, thus indicating that 4-oxo-4-HPR antitumor effect is due
to at least two independent mechanisms of action.
Results
ROS generation participates in 4-oxo-4-HPR-induced
apoptosis in A2780 cells
We have recently reported that 4-HPR triggers apoptosis
through activation of a signaling cascade that starts from ROS
generation and that involves ER stress responses, JNK activation
and PLAB upregulation [9]. To investigate if the signaling cascade
responsible for 4-HPR-induced apoptosis was also involved in the
apoptosis induced by 4-oxo-4-HPR, we first analyzed the
involvement of ROS generation in the apoptosis induced by 4-
oxo-4-HPR in A2780, a human ovarian carcinoma cell line,
chosen because it is already known to be responsive to the retinoid
(IC50 =0.6 mM in a 72 hours assay) and to generate ROS in
response to 4-oxo-4-HPR treatment [12]. The involvement of
ROS production was assayed by evaluating the effect of the
antioxidant vitamin C on 4-oxo-4-HPR-induced apoptosis. Five
mM 4-oxo-4-HPR treatment for 4 hours caused an increase of
ROS production, that was prevented by the addition of 100 mM
vitamin C (Figure 1A). Abrogation of ROS generation by vitamin
C caused a reduction (1.7 fold) on 4-oxo-4-HPR-induced
apoptosis, evaluated as DNA fragmentation by an Elisa assay
(Figure 1B). A similar apoptosis reduction has been observed
through the determination of sub-G1 population by propidium
iodide staining followed by flow cytometry analysis (see Figure 5
and relative result paragraph). These data suggested that ROS
generation induced by 4-oxo-4-HPR was involved in 4-oxo-4-
HPR-induced apoptosis.
4-oxo-4-HPR induces ER stress response in A2780 cells
We analyzed whether 4-oxo-4-HPR, like 4-HPR [9], activated,
downstream of ROS generation, an ER stress response, by
evaluating ER-stress specific signals: the post-transcriptional
splicing of the transcription factor X-box binding protein-1
(XBP-1), the expression of the chaperon proteins glucose-regulated
protein 78 KD (GRP-78)/immunoglobulin-binding protein (Bip)
and the heat shock protein 70 (HSP70), and the phosphorylation
status of the alpha-subunit of eukaryotic initiation factor 2 (eIF2a)
[14]. In A2780 cells, 5 mM 4-oxo-4-HPR treatment for 24 hours
induced the splicing of a 25 bp intron from the XBP-1 precursor
mRNA, caused upregulation of GRP78/Bip and HSP70 and
phosphorylation of eIF2a (Figure 2A). The activation of these ER
stress-associated events was abrogated (XBP-1, GRP78/Bip and
HSP70) or strongly reduced (eIF2a) by the addition of vitamin C
(Figure 2A). The results indicated that 4-oxo-4-HPR caused
induction of ER stress response, as downstream event of ROS
generation.
4-oxo-4-HPR induces JNK activation in A2780 cells
We analyzed whether 4-oxo-4-HPR, like 4-HPR [9], induced
JNK activation. Western blot analysis, in A2780 cells, showed that
5 mM 4-oxo-4-HPR treatment for 24 hours caused JNK phos-
phorylation and that the addition of vitamin C strongly reduced
the activation of the kinase (Figure 2B). The data indicated that 4-
oxo-4-HPR induced the activation of JNK and that this event
occurred through a ROS-dependent mechanism.
Figure 1. Effects of vitamin C treatment on 4-oxo-4-HPR-
induced ROS generation and apoptosis. (A) Analysis of ROS
production in A2780 cells treated for 4 hours with 5 mM 4-oxo-4-HPR,
with or without 100 mM vitamin C. The analysis was performed by flow
cytometry after addition of the redox-sensitive dye CM-H2DCFDA. The
graph shows representative flow cytometry fluorescence profiles in
different conditions of treatment (one representative experiment of
three). A shift to the right from control indicates increased ROS levels.
(B) A2780 cells were treated for 24 hours with 5 mM 4-oxo-4-HPR, with
or without 100 mM vitamin C and apoptosis, evaluated as DNA
fragmentation, was measured by an ELISA assay. Data are means of
three independent experiments; vertical bars are standard deviations.
Asterisk indicates significant difference (P,0.05).
doi:10.1371/journal.pone.0013362.g001
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induced by 4-oxo-4-HPR
We have previously reported that PLAB is upregulated by 4-
HPR in a ROS dependent manner [9], and that it plays a
functional role in apoptosis induced by the retinoid in A2780 cells
[10]. We thus evaluated whether also 4-oxo-4-HPR modulated
PLAB expression. Western blot analysis showed that 5 mM 4-oxo-
4-HPR treatment for 24 hours induced PLAB upregulation and
that this effect was strongly reduced by the addition of vitamin C
(Figure 3A). To investigate whether PLAB upregulation played a
functional role in the apoptosis induced by 4-oxo-4-HPR, we took
advantage of PLAB silencing in A2780 cells, previously generated
by stable transfection [10]. As expected, PLAB upmodulation
induced by 4-oxo-4-HPR was strongly reduced in cells transfected
with the PLAB siRNA plasmid compared with cells transfected
with a scrambled plasmid used as control (Figure 3B). As shown in
Figure 3C, the apoptosis induced by 4-oxo-4-HPR in cells
transfected with PLAB siRNA was approximately 2-fold reduced
versus the cells transfected with the scrambled plasmid. The
Figure 2. Effects of 4-oxo-4-HPR and vitamin C treatments on
ER stress marker expression and JNK phosphorylation. (A)
A2780 cells treated for 24 hours with 5 mM 4-oxo-4-HPR, with or
without 100 mM vitamin C, were subjected to RT-PCR assay to analyze
the splicing of the 25 bp intron from XBP-1 transcript and western blot
analysis for the expression of GRP-78/Bip, peIF2a, eIF2a. For reverse
transcription–PCR, b-actin was amplified as internal control. For western
blot analysis, as a control for loading, the blot was incubated with actin
antibody. (B) Cells treated as in (A) were subjected to western blot
analysis for the expression of pJNK and JNK.
doi:10.1371/journal.pone.0013362.g002
Figure 3. Role of PLAB upmodulation in 4-oxo-4-HPR-induced
apoptosis. (A) Western blot analysis for PLAB expression in A2780 cells
treated for 24 hours with 5 mM 4-oxo-4-HPR, with or without 100 mM
vitamin C. As a control for loading, the blot was incubated with actin
antibody. (B) Western blot analysis for PLAB expression in A2780 cells
stably transfected with a plasmid containing a PLAB siRNA or a
scrambled nonsilencing siRNA following addition of 5 mM 4-oxo-4-HPR
for 24 hours. As a control for loading, the blot was incubated with actin
antibody. (C) Detection of 4-oxo-4-HPR-induced apoptosis in A2780
stably transfected with a plasmid containing a PLAB siRNA (black
columns) or a scrambled nonsilencing siRNA (grey columns). Transfect-
ed cells were treated for 24 hours with 5 mM 4-oxo-4-HPR and
apoptosis, evaluated as DNA fragmentation, was measured by an ELISA
assay. Data are means of four independent experiments; vertical bars
are standard deviations. Asterisk indicates significant difference
(P,0.01).
doi:10.1371/journal.pone.0013362.g003
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cells has also been confirmed by evaluation of sub-G1 population
after propidium iodide staining (data not shown). The results
demonstrated that 4-oxo-4-HPR induced PLAB upregulation as
an event downstream of ROS generation and that PLAB
contributed to 4-oxo-4-HPR-induced apoptosis. All the aforemen-
tioned data suggested that 4-oxo-4-HPR caused the activation of
the ROS-related signalling cascade already shown to be activated
by 4-HPR (ROS R ER stress R JNK R PLAB) [9].
4-oxo-4-HPR induces Bcl-2 and Mcl-1 downregulation in
a ROS-independent manner
Since it has been reported that 4-HPR can induce apoptosis
through regulation of members of the Bcl-2 family, as downstream
event of ROS generation [15–17], we analyzed the effect of 4-oxo-
4-HPR on the antiapoptotic proteins B cell lymphoma gene-2 (Bcl-
2) and myeloid cell leukemia-1 (Mcl-1) and on the proapoptotic
protein Bcl-2-associated X protein (Bax). In A2780 cells, 5 mM4 -
oxo-4-HPR treatment for 24 hours caused a decrease of Bcl-2 and
Mcl-1 protein expression level, whereas had not effect on Bax
expression (Figure S1). The downregulation of both Bcl-2 and
Mcl-1 was not prevented by the addition of vitamin C (Figure S1),
thus suggesting that 4-oxo-4-HPR caused such a decrease in a
ROS-independent manner.
Mitotic arrest and formation of multipolar spindles are
independent from ROS-related signaling cascade in
A2780 cells
Contrary to 4-HPR, which only slightly affects the G1 phase of
the cell cycle, 4-oxo-4-HPR causes a marked accumulation of cells
in G2-M phases[12]. We have recently reported that 4-oxo-4-HPR-
induced cell cycle perturbation was due to the ability of the retinoid
to inhibit tubulin polymerization, arresting cells in mitosis [13].
Moreover, the antimitotic effect of the retinoid was shown to be
coupled with formation of aberrantly shaped spindles (i.e. multi-
polars) due to its effects on tubulin polymerization [13]. To
investigate whether the 4-oxo-4-HPR-induced mitotic arrest and
the formation of multipolar spindles were related to the ROS-
induced signaling cascade we first performed a time-course analysis
of both ROS generation and cell cycle perturbation induced by 4-
oxo-4-HPR. ROS generation was observed as early as 30 minutes
after retinoid treatment (Figure 4A) and stayed throughout the 24-
hour time-course. By contrast, a slight G2-M cell accumulation was
observed only at 2 hours and the increase of the percentage of G2-
M arrested cells was time-dependent up to 16-24 hours (Figure 4B).
The time-course analysis thus revealed that the oxidative stress
induced by 4-oxo-4-HPR occurred earlier than the cell cycle arrest
and that the two events presented different kinetics. To investigate
whether the 4-oxo-4-HPR-induced ROS generation played a role
in the mitotic arrest, we analyzed the effects of vitamin C on cell
cycle perturbation and formation of aberrant spindles induced by
the retinoid. In A2780 cells exposed for 24 hours to 5 mM 4-oxo-4-
HPR, the addition of 100 mM vitamin C did not prevent the
accumulation of G2-M cell population (Figure 5 and S2) or the
formation of multipolar spindles (Figure 5). Consistent results in cell
cycle distribution and formation of multipolar spindles were
obtained by inhibiting the ROS-related signaling cascade at a
downstream level through PLAB silencing: transfection with PLAB
siRNA did not prevent 4-oxo-4-HPR-induced mitotic arrest and
formation of multipolar spindles (data not shown). The results
indicated that in A2780 cells, the mitotic arrest induced by 4-oxo-4-
HPR was neither an event downstream of ROS generation, nor a
step of the ROS-related signaling cascade.
4-oxo-4-HPR acts through a double mechanism of action
also in cancer cell lines of different histotypes
To determine whether the involvement of the two independent
mechanisms in 4-oxo-4-HPR activity was restricted to A2780 cells
or represented the distinctive mode of action of the retinoid, we
extended the analysis of 4-oxo-4-HPR effects to three others
human cancer cell lines responsive to the retinoid: T47D
(mammary adenocarcinoma), HeLa (epithelial cervical adenocar-
cinoma) and SK-N-BE (neuroblastoma) cells (Figure 6A). We first
assessed the intracellular generation of ROS induced by 4-oxo-4-
HPR showing that, in the three cancer cell lines, 5 mM 4-oxo-4-
HPR for 4 hours increased ROS production over controls and
that the addition of 100 mM vitamin C inhibited the ROS
generation induced by the retinoid (Figure 6B). In the three tested
cell lines, 4-oxo-4-HPR treatment induced PLAB upregulation
and this effect was reduced by the addition of vitamin C
(Figure 6C). We then performed cell cycle analysis showing that
4-oxo-4-HPR treatment induced a marked G2-M cell cycle arrest
in all tested cancer cell lines (Figure 7 and S2). Similarly to what
observed in A2780 cells, in these cell lines the inhibition of ROS
generation with vitamin C caused a marked reduction of sub-G1
population, but did not decrease the percentage of cells arrested in
G2-M phase (Figure 7 and S2). Moreover, 4-oxo-4-HPR treatment
caused formation of multipolar spindles in T47D, HeLa and SK-
N-BE cells (Figure 7), and in all of them the addition of vitamin C
did not prevent the formation of aberrant spindles induced by the
retinoid (Figure 7). The results suggested that, also in T47D, HeLa
and SK-N-BE cells, the ROS-dependent signaling cascade was
involved in 4-oxo-4-HPR-induced apoptosis. Moreover, 4-oxo-4-
HPR-induced cell cycle arrest and the formation of multipolar
spindles were independent from the ROS-associated signaling
cascade, not only in ovarian but also in breast, cervical and
neuroblastoma cancer cell lines, revealing the distinctive feature of
4-oxo-4-HPR to have a double mechanism of action.
Discussion
4-oxo-4-HPR is a polar metabolite of the synthetic retinoid 4-
HPR that was detected in plasma samples of women treated with 4-
HPR participatingin a Phase III breast cancer prevention trial [11].
Our previous in vitro studies conducted with 4-oxo-4-HPR have
shown that the retinoid is endowed with very promising anticancer
properties, such as higher tumour growth inhibitory effects than 4-
HPR (being its IC50 values two to four times lower than the parent
drug in the majority of tested cell lines), lack of cross resistance and
synergistic interaction with the parent drug [12], suggesting that it
might be proposed as a new agent for cancer therapy. Differently
from 4-HPR and other retinoids, 4-oxo-4-HPR targets microtu-
bules and inhibits tubulin polymerization causing mitotic arrest and
formationofmultipolarspindleswithoutlossofcentrosomeintegrity
[13]. On the other hand, similarly to the parent drug, 4-oxo-4-HPR
induces increase of ROS generation [12].
Since the 4-HPR-induced ROS generation has been shown to
activate an apoptotic cascade involving ER stress response, JNK
activation and upregulation of the proapoptotic protein PLAB [9],
we decided to investigate whether 4-oxo-4-HPR triggered
apoptosis also via ROS generation and whether its antimitotic
activity was related to this ROS-dependent pathway. 4-oxo-4-
HPR-induced ROS production contributed to the apoptotic
activity of the retinoid, because the treatment with the antioxidant
vitamin C caused a reduction of 4-oxo-4-HPR-induced apoptosis.
In our previous study on 4-oxo-4-HPR characterization [12], we
were not able to show a clear causal relationship between
generation of ROS and cell growth inhibitory activity of the
Double Action of 4-oxo-4-HPR
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in the previous analysis (i.e. N-acetyl-L-cysteine) did not totally
prevent the oxidative stress induced by 4-oxo-4-HPR, but only
caused a partial reduction of ROS production [12].
Downstream of ROS generation, 4-oxo-4-HPR activated other
signaling intermediates of the 4-HPR apoptotic cascade, such as
ER stress response (detected by XBP-1 splicing, GRP78/Bip and
HSP70 upregulation, and eIF2a phosporylation) and JNK
phosporylation, both prevented by vitamin C addition. The
expression of the proapoptotic protein PLAB was dramatically
increased by 4-oxo-4-HPR and its upregulation was reduced by
vitamin C addition, suggesting that the protein expression
modulation was a downstream event of the oxidative stress
induced by the retinoid. Moreover, we demonstrated that PLAB
played a functional role in 4-oxo-4-HPR apoptotic activity,
because its silencing decreased the apoptosis induced by the
retinoid. Therefore, our results indicated that 4-oxo-4-HPR,
besides acting as an antimicrotubule agent, induced apoptosis
via the signaling cascade that we have already shown to be
activated by 4-HPR (ROS R ER stress R JNK R PLAB) [9].
PLAB apoptotic-inducing activity has been observed and reported
by other authors in several cellular contexts and following treatment
with different anticancer agents [9,18-21]. However, the specific
downstreameventsbywhichPLABmediatessucheffectremain to be
determined. From our results, an involvement of the proteins Bcl-2
and Mcl-1, a Bcl-2 family member, in PLAB apoptotic activity might
be possibly excluded. In fact, even though 4-oxo-4-HPR treatment
caused a downregulation of the expression level of the two
Figure 4. Effects of 4-oxo-4-HPR treatment at different time points on ROS generation and cell cycle distribution. (A) Analysis of ROS
production in A2780 cells treated with 5 mM 4-oxo-4-HPR for 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 16 hours, and 24 hours. The analysis was
performed by flow cytometry after addition of the redox-sensitive dye CM-H2DCFDA. The graphs show representative flow cytometry fluorescence
profiles in different conditions of treatment (one representative experiment of three). A shift to the right from control indicates increased ROS levels.
(B) Flow cytometric analysis of propidium iodide-stained A2780 cells treated with vehicle or 5 mM 4-oxo-4-HPR for 30 minutes, 1 hour, 2 hours,
4 hours, 6 hours, 16 hours, and 24 hours. Numbers in the figure indicate the percentage of cells in the phase of cell cycle, according to the analysis
performed with ModFit LT software. One experiment representative of three is shown.
doi:10.1371/journal.pone.0013362.g004
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inhibition of the ROS-mediated apoptotic cascade involving PLAB.
It is interesting to note that 4-oxo-4-HPR is an oxidized form of
4-HPR and that the modification in position 4 of the cyclohexene
ring is probably responsible for 4-oxo-4-HPR antimicrotubule
activity, but does not affect the ability of the retinoid to induce
ROS generation and to activate the ROS-related signalling
cascade. Such chemical modification could be also responsible
for the different sphingolipid metabolism observed between the
two retinoids. Both 4-HPR and 4-oxo-4-HPR have been shown to
induce a dramatic increase of dihydroceramide production;
however, the contribution of distinct molecular species to the
total increment was reported to be markedly different, in terms of
sphingosine/sphinganine and fatty acid content. In addition, 4-
oxo-4-HPR, contrary from the parent drug, has been shown to
slightly increase also the ceramide production [22].
We have previously reported that 4-oxo-4-HPR acts atypically
compared to 4-HPR and other retinoids, due to its ability to
Figure 5. Effects of 4-oxo-4-HPR and vitamin C treatments on cell cycle distribution and spindle assembly. Flow cytometric analysis of
propidium iodide-stained A2780 cells treated for 24 hours with 5 mM 4-oxo-4-HPR with or without 100 mM vitamin C. Numbers in the figure indicate
the percentage of cells in the phase of cell cycle, according to the analysis performed with ModFit LT software. One experiment representative of
three is shown. On the right is depicted a representative mitotic cell image for each treatment, obtained by immunostaining with a-tubulin antibody
(green) and nuclear staining with Hoechst 33342 (blue). Scale bar =5 mm.
doi:10.1371/journal.pone.0013362.g005
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spindles and mitotic arrest [13]. In this study we have found that
the mitotic arrest and the coupled formation of multipolar spindles
induced by 4-oxo-4-HPR were independent from the ROS-related
signaling cascade. In fact, we have shown that 4-oxo-4-HPR-
induced ROS generation occurred earlier than the mitotic arrest,
thus indicating that the antimitotic activity of the retinoid was not
an event upstream the oxidative stress. On the other hand, the
inhibition of the ROS-related pathway by vitamin C or by PLAB
silencing did not prevent the ability of 4-oxo-4-HPR to exert its
antimicrotubule activity, thus suggesting that the mitotic arrest was
not a ROS-dependent mechanism. The occurrence of a double
mechanism of action could plausibly be a distinctive feature of the
mode of action of 4-oxo-4-HPR, since these two unrelated
pathways were found in cancer cell lines of different histotypes
(ovarian, breast, cervical carcinoma and neuroblastoma).
Even though the exact mechanism by which 4-oxo-4-HPR
antimicrotubule activity triggers cell death has yet to be determined,
on the basis of the abovementioned data, we can speculate that both
the ROS-related signaling cascade and the antimicrotubule activities
Figure 6. Effects of 4-oxo-4-HPR and vitamin C treatments on ROS generation and PLAB expression. (A) Citotoxic effect of 4-oxo-4-HPR
on T47D (%), HeLa (n) and SK-N-BE (#) cell growth was estimated by using the sulforhodamine B assay. The antiproliferative activity of 4-oxo-4-HPR
in each cell line was tested in three independent experiments with four replicate wells for each analysis; vertical bars are standard deviations. (B)
Analysis of ROS production in T47D, HeLa and SK-N-BE cells treated for 4 hours with 5 mM 4-oxo-4-HPR, with or without 100 mM vitamin C. The
analysis was performed by flow cytometry after addition of the redox-sensitive dye CM-H2DCFDA. The graphs show representative flow cytometry
fluorescence profiles in different conditions of treatment (one representative experiment of three). A shift to the right from control indicates
increased ROS levels. (C) Western blot analyses for PLAB expression in T47D, HeLa and SK-N-BE cells treated with 5 mM 4-oxo-4-HPR for 24 hours, with
or without 100 mM vitamin C. As a control for loading, the blot was incubated with actin antibody.
doi:10.1371/journal.pone.0013362.g006
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and we propose that the retinoid acts as presented schematically in
Figure 8. Nonetheless, the analysis of 4-oxo-4-HPR mechanisms of
action will need further studies to investigate how the two pathways
molecularly lead to cell death. It is tempting to speculate that the
ROS-independent downregulation of Bcl-2 and Mcl-1, observed
after 4-oxo-4-HPR treatment, could play a role in the apoptosis
induced by the antimicrotubule activity of the retinoid, although at
present no evidence supports this hypothesis. According to our
observations, it has been reported that treatment with other
microtubule-interfering agents can lead to a decrease in Bcl-2 and
Mcl-1 intracellular amounts contributing to apoptosis [23–25].
It is noteworthy that other microtubule-targeted agents have been
shown to promote ROS generation in cancer cells, but the
relationship between tubulin dynamics and oxidative stress remain
unclear [26–33]. Recently, the anticancer activity of paclitaxel has
been linked to the generation of intracellular and extracellular ROS
and it has been suggested that the disturbance of microtubule
polymerization state induced by this agent, as well as by taxotere or
vincristine, could enhance ROS production through stabilization of
Figure 7. Effects of vitamin C treatment on 4-oxo-4-HPR antimitotic activities in T47D, HeLa and SK-N-BE cells. Flow cytometric
analysis of propidium iodide-stained T47D (A), HeLa (B) and SK-N-BE (C) cells treated for 24 hours with 5 mM 4-oxo-4-HPR with or without 100 mM
vitamin C. Numbers in the figure indicate the percentage of cells in the phase of cell cycle, according to the analysis performed with ModFit LT
software. One experiment representative of three is shown. On the bottom of each histogram, immunofluorescence analysis with a-tubulin antibody
(green) of cells treated in the same way. Nuclear morphology was visualized by staining with Hoechst 33342 (blue). Scale bar =10 mm.
doi:10.1371/journal.pone.0013362.g007
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the antiproliferative effect of patupilone, a member of the
microtubule-stabilizing agents epothilones, and a causal relationship
between the oxidative stress and the modifications of microtubule
dynamics has been suggested [30]. By contrast, the ROS generation
induced by stilbene 5c, a microtubule inhibitor at the colchicine site,
has been shown to be unrelated to the drug-induced cell cycle
perturbation [29], similarly to what we have found for 4-oxo-4-HPR.
The ability of 4-oxo-4-HPR to act through at least two
unrelated mechanisms could probably allow to counteract the
development of drug resistance. In fact, we have shown that if one
pathway is inhibited (i.e. ROS-related signaling pathway), the
retinoid is able to act through the other mechanism (i.e. mitotic
arrest) to kill cancer cells. In addition, the knowledge of the
mechanisms underlying 4-oxo-4-HPR antiproliferative activity
might facilitate future design of drug combination strategies.
In conclusion, the new information provided by our study on the
mechanism of action of 4-oxo-4-HPR is that the retinoid exerts its
activity through at least two independent pathways that contribute
to its antiproliferative effect, i.e. the ROS-related signaling cascade
and the antimicrotubule activity. The finding of a double
mechanism underlying anticancer activities of 4-oxo-4-HPR
provides an explanation of the ability of 4-oxo-4-HPR to be more
potent than the parent drug and to be effective also in 4-HPR-
resistantcell lines(i.e.A2780/HPR cells)[12].This distinctivemode
of action could allow 4-oxo-4-HPR to efficiently target tumor and
eventually to counteract the development of drug resistance.
Materials and Methods
Cell lines and reagents
Ovarian tumour cell line A2780 (obtained from Dr. Ozols,
Bethesda, MD) and neuroblastoma cell line SK-N-BE, purchased
from ATCC (Manassas, VA, USA), were maintained in RPMI 1640
(Lonza, Basel, Switzerland) containing 10% fetal calf serum. Breast
tumour cell line T47-D (obtained from Dr. R. Sutherland, Sydney,
New South Wales, Australia) was maintained in RPMI 1640
containing 10% fetal calf serum and 0.25 U/mL insulin. Cervical
carcinoma cellline HeLa, purchased from ATCC,was manteined in
Dulbecco’s Modified Eagle medium (Gibco Brl, Paisley, UK)
supplemented with 10% fetal bovine serum. Stably transfected
A2780 cells with PLAB siRNA or a scrambled nonsilencing siRNA
were generated previously [10] and maintained in RPMI 1640
medium supplemented with 10% fetal calf serum and containing
G418 (Gibco) at a concentration of 400 mg/ml. All cell lines were
cultured at 37uCu n d e r5 %C O 2. 4-oxo-4-HPR, synthesized as
previously described [11], was dissolved at 10 mmol/L in DMSO
prior to further dilution in culture medium and stored at –80uCi n
the dark. Vitamin C (Sigma, St Louis, MO, USA) was added to cells
1 h before 4-oxo-4-HPR treatment.
Growth inhibition assay
T47D, HeLa and SK-N-BE cells were seeded in 96-well tissue
culture plates at 7610
3 cells/well and were allowed to adhere for
24 hours before treatment. Cells were grown in the presence of vehicle
or 4-oxo-4-HPR at a final concentration of 0.3, 1, 3, 5, and 10 mM( 4
wells for each treatment). Cellular growth was assessed after 72 hours
by sulforhodamine B (SRB) assay. Briefly, proteins were precipitated
with 10% trichloroacetic acid for 1 hour at 4uC and stained for 30
minutes with SRB dye 0.4% w/v in acetic acid 1% v/v. Finally,
precipitated proteins were washed and solubilized in Tris buffer
10 mM. Absorbance [optical density (OD)] was measured at 540 nm
by using a microplate reader. For each treatment, cell survival was
estimated from the equation: % cell survival =1006At/Ac, where At
and Ac are the absorbencies of the sulforhodamine B color reaction in
treated and control cultures, respectively. The antiproliferative activity
of 4-oxo-4-HPR in each cell line was tested in three independent
experiments with four replicate wells for each analysis.
Determination of reactive oxygen species
Intracellular production of ROS was detected by using of the
oxidation-sensitive dye 5-(and-6)-chloromethyl-29,79-dichlorodihy-
drofluorescein diacetate (CM-H2DCFDA; Molecular Probes, Inc.,
Eugene, OR) as described previously [12]. Briefly, cells (8610
5 per
well) were plated in six-well cell culture plates and incubated for
different time points in the presence of 5 mM 4-oxo-4-HPR.
Medium was discarded and, under low light conditions, replaced
with 50 mM CM-H2DCFDA in whole medium for 20 minutes at
37uC. Cells were harvested, transferred to foil-wrapped tubes and
analyzed immediately by flow cytometry.
Immunoblot analysis
Proteins were extracted by lysing cells in sodium dodecyl sulfate
(SDS) sample buffer (62.5 mM Tris–HCl [pH 6.8], 2% SDS)
containing 1 mM phenylmethylsulfonyl fluoride, 10 mg/mL pepstatin,
12.5 mg/mL leupeptin, 2 mg/mL aprotinin, 1 mM sodium orthova-
nadate, and 1 mM sodium molybdate. Cell extracts were processed for
western immunoblotting as described previously [34]. The following
antibodies used for immunoblotting were purchased from the indicated
Figure 8. Scheme showing proposed cascade of events
involved in 4-oxo-4-HPR-induced growth inhibitory effect. 4-
oxo-4-HPR induces cell death through two independent mechanisms of
action: 1) a ROS-related signaling cascade involving ER stress response,
JNK activation and upregulation of the proapoptotic protein PLAB; and
2) antimicrotubule activities consisting in inhibition of tubulin
polymerization, mitotic arrest and formation of multipolar spindles.
doi:10.1371/journal.pone.0013362.g008
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(Santa Cruz, CA, USA); HSP70, phospho-JNK (Thr183/Tyr185),
JNK1/2, phospho-eIF2a,e I F 2 a and Mcl-1 from Cell Signaling
Biotechnology (Beverly, MA, USA), Bcl-2 from DakoCytomation
(Glostrup, Denmark), and Bax and actin from Sigma.
Apoptosis evaluation
Fragmentation of DNA was determined by photometric enzyme
immunoassay using Cell Death Detection ELISAplus kit (Roche,
Penzberg, Germany) according to the manufacturer’s instruction.
Briefly, cells (1610
4 per well) were seeded in 96-well cell culture
plates and treated the day after. Adherent and floating cells were
then lysed and centrifuged and cytoplasmic fractions containing
fragmented DNA were transferred to streptavidin-coated micro-
titer plates and incubated for 2 hours at room temperature with a
mixture of anti–histone-biotin and anti–DNA-peroxidase antibod-
ies. Quantitative determination of the amount of nucleosomes by
the peroxidase retained in the immunocomplex was determined
photometrically with 2,29-azino-di-[3-ethylbenz-thiazoline-sulfo-
nate-6-diammonium salt] as peroxidase substrate. DNA fragmen-
tation in control and treated cells was expressed as absorbance at
405 nm. The apoptosis was also determined by the evaluation of
the sub-G1 population by propidium iodide staining followed by
flow cytometry analysis (see cell cycle analysis description).
XBP-1 RT-PCR splicing assay
Reverse transcription polymerase chain reaction (RT-PCR)
analysis was performed as described elsewhere [34]. XBP-1
cleavage assay was performed as previously described [35]. Briefly,
XBP-1 was amplified using the gene-specific oligonucleotide
primers: hXBP1.3S, 59-A AAC AGA GTA GCA GCT CAG
ACT GC-39 and mXBP1.12AS, 59- TC CTT CTG GGT AGA
CCT CTG GGA G -39. The PCR reaction cycle included 2
minutes of denaturation at 94uC followed by 35 cycles of 94uC for
30 seconds, 60uC for 30 seconds, and 72uC for 30 seconds. To
distinguish the unspliced (473 bp) from the spliced (450 bp) band
the PCR products were separated on a 3% agarose gel and
visualized by UV after ethidium bromide staining.
Cell cycle analysis
For analysis of cell cycle distribution, cells (9610
5) were plated into
100-mm tissue culture dishes and at approximately 30% confluence
treated with 5 mM 4-oxo-4-HPR and/or 100 mM vitamin C. At
different time points after the treatment, floating and attached cells
were collected and washed twice with PBS, fixed in ice cold 70%
ethanol and stored at -20uC until use. Subsequently, cells were rinsed
with PBS and incubated with PBS containing 20 mg/mL propidium
iodide (Sigma) and 1 mg/mL RNase A (Sigma). Cell cycle analysis
was done using FACScan flow cytometer (Becton Dickinson, San
Jose, CA). The percentage of cells in different phases of cell cycle was
determined by ModFit LT cell cycle analysis software (Verity
Software House, Topsham, ME), considering only cells with DNA
content $2n. Apoptotic cells were identified as a sub-G1 population
(DNA content ,2n) and the percentage of cells in this pre-phase was
calculated considering the totality of the events.
Immunofluorescence Analysis
Cells, grown on glass coverslips slides in 24 mm Petri dishes,
were fixed in 100% methanol at –20uC for 7 minutes, washed with
PBS and then blocked at room temperature for 1 hour in 3%
BSA/0.1% (v/v) Triton X-100/PBS. Cells were incubated
overnight at 4uC in primary antibody, washed three times with
PBS, and then incubated for another hour at room temperature
with secondary antibody, washed with PBS and stained with
Hoechst 33342 (Sigma) 2 mg/ml in PBS for 2 minutes. Slides were
mounted with 0.1% (v/v) Mowiol (Calbiochem, San Diego, CA,
USA) and viewed with a fluorescence microscope [images were
recorded with a Spot Insight digital camera (Delta Sistemi)
equipped with a system of image analysis (IAS 2000; Delta
Sistemi)]. The following antibody was used: mouse anti-a-tubulin
(Sigma). The secondary antibody used was anti-mouse Alexa 488
(Molecular Probes).
Statistical analysis
Experiments and in vitro assays were carried out at least in
triplicate. Differences between mean values were assessed by
Student’s t-test with two-sided P values ,0.05 considered as
statistically significant.
Supporting Information
Figure S1 Effects of 4-oxo-4-HPR and vitamin C treatments on
the expression of Bcl-2 family members. A2780 cells treated for
24 hours with 5 mM 4-oxo-4-HPR, with or without 100 mM
vitamin C, were subjected to western blot analysis for the
expression of Mcl-1, Bcl-2 and Bax. As a control for loading, the
blots were incubated with actin antibody.
Found at: doi:10.1371/journal.pone.0013362.s001 (0.51 MB TIF)
Figure S2 Effects of 4-oxo-4-HPR and vitamin C treatments on
G2-M cell accumulation. Flow cytometric analysis of propidium
iodide-stained A2780, T47D, HeLa and SK-N-BE cells treated for
24 hours with 5 mM 4-oxo-4-HPR with or without 100 mM
vitamin C. Histograms show the percentage of cells in G2-M
phase, according to the analysis performed with ModFit LT
software. Data are means of three independent experiments;
vertical bars are standard deviations. Asterisk indicates significant
difference (P,0.05).
Found at: doi:10.1371/journal.pone.0013362.s002 (0.47 MB TIF)
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